A key aspect of debates about the efficiency of the biopharmaceutical industry in generating new medicines is the role of small and medium-sized enterprises (SMEs) and universities as sources of pharmaceutical innovation. Some of the most important recent therapeutics and vaccines did not emerge directly from large drug companies, but rather were acquired through asset licensing, buy-outs of biotech firms, or came from publicly funded academic spin-offs. Furthermore, SMEs play a pivotal role as innovation sources in high priority areas for public health, such as antimicrobial research and development (R&D). This has been highlighted in the COVID-19 pandemic, with crucial vaccines and drugs identified by academic institutions and/or SMEs being developed through partnerships with larger biopharma companies.
Novartis Kisqali reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer Novartis presents new patient-reported outcomes (PRO) data from the phase III...
Moderna shares positive phase 3 results for mRNA influenza vaccine candidate Moderna has shared positive results from a late-stage trial of its influenza vaccine, with mRNA-1010 shown to generate a stronger immune...
Ensifentrine Under Review for Maintenance Treatment of COPD The Food and Drug Administration has accepted the New Drug Application for ensifentrine for the maintenance treatment of patients with chronic obstructive...
